Safety
leukopenia, cancer, anemia, rash, lymphopenia, TRAEs
HYPERSENSITIVITY REACTIONS, LEUKOPENIA, ADVERSE EVENTS, CANCER, ANEMIA, LYMPHOPENIA
All of the 60 patients were included in the safety analysis. The median cycle of camrelizumab was 4 cycles (range, 4–28). A total of 55 (91.7%) of the 60 patients experienced at least one TRAE (Efficacy of each cancer types.NE; Not available.Treatment related adverse events.TRAEs leading to camrelizumab treatment interruption occurred in 7 patients (11.7%). Patients discontinued camrelizumab because of TRAEs that were lymphopenia and leukopenia. TRAEs leading to apatinib treatment interruption occurred in 10 patients (16.7%). Only three patients discontinued liposomal irinetocan owing to hypersensitivity reactions during infusion.Immune-related AEs (irAEs) of any grade occurred in 47 (78.3%) patients, and the most frequent irAEs were lymphocyte count decreased (56.7%), white blood cell count decreased (31.7%), anemia (30.0%), and rash (26.7%).